RÉSUMÉ
To provide insight into the pharmacological changes in the peripheral blood (PB) molecular profile induced by tumor necrosis factor (TNF)-blockade in patients with rheumatoid arthritis (RA), blood was obtained in PAXgene tubes from 33 RA patients before and 1 month after TNF-blocking therapy (infliximab). From 15 randomly chosen patients pre- and post-treatment gene expression profiles were determined. The remaining 18 RA patients served as validation cohort. A group-based paired analysis of the gene expression profiles from the post- vs pre-treatment samples revealed a signature of genes significantly regulated by TNF-blockade. Downregulated genes reflected several biological pathways such as inflammation, angiogenesis, B- and T-cell activation. Further analysis revealed that the pharmacological response signature was significantly regulated in all treated patients, irrespective of clinical response, which is indicative for the presence of an active TNF pathway in all RA patients. The data imply that all patients carried features of TNF bioactivity irrespective of clinical response. These results favor a model for the parallel presence of TNF-dependent and TNF-independent pathways in the individual RA patient. Clinical response status to TNF-blockade may be dependent on the relative contribution of TNF-independent effector pathways.
Sujet(s)
Anticorps monoclonaux/pharmacologie , Antirhumatismaux/pharmacologie , Polyarthrite rhumatoïde/traitement médicamenteux , Polyarthrite rhumatoïde/génétique , Régulation de l'expression des gènes , Adulte , Sujet âgé , Polyarthrite rhumatoïde/sang , Polyarthrite rhumatoïde/anatomopathologie , Cellules sanguines/métabolisme , Études cas-témoins , Femelle , Analyse de profil d'expression de gènes , Humains , Infliximab , Mâle , Adulte d'âge moyen , Pharmacogénétique , Transduction du signal/génétique , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Facteur de nécrose tumorale alpha/métabolismeRÉSUMÉ
The objective of this study was to identify molecular profiles that may distinguish clinical subtypes in systemic sclerosis (SSc). Large-scale gene expression profiling was performed on peripheral blood (PB) from 12 SSc patients and 6 healthy individuals. Significance analysis of microarrays, two-way hierarchical cluster analysis and PANTHER (Protein ANalysis THrough Evolutionary Relationships) ontology classification were used to analyze the data. Quantitative PCR was applied for validation in a cohort of 43 SSc patients. The results show that the expression of genes involved in immune defense, cell cycle and signal transduction was significantly elevated in PB of SSc patients (n=12) compared with healthy individuals (n=6). SSc patients could be stratified into subgroups based on differential expression of genes induced by type I interferon (IFN) and genes involved in antimicrobial (AM) activity. Differential expression of type I IFN or AM signature genes was validated and extended in an independent cohort of 31 patients by quantitative PCR. Low expression of IFN response genes was associated with the presence of anti-centromere antibodies, whereas increased expression was associated with the appearance of digital ulcers. In conclusion, patients with SSc can be classified on the basis of differential expression of immune defense genes. Differences in the activity of the type I IFN response program stratify patients into two clinically relevant subgroups.
Sujet(s)
Anticorps antinucléaires/immunologie , Centromère/immunologie , Interféron de type I/génétique , Sclérodermie systémique/génétique , Ulcère cutané/génétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Études de cohortes , Régulation négative/génétique , Régulation négative/immunologie , Femelle , Doigts , Analyse de profil d'expression de gènes , Humains , Interféron de type I/immunologie , Mâle , Adulte d'âge moyen , Sclérodermie systémique/classification , Sclérodermie systémique/immunologie , Ulcère cutané/immunologie , Régulation positive/génétique , Régulation positive/immunologieRÉSUMÉ
Rheumatoid arthritis (RA) is a heterogeneous disease with unknown etiology. Here we aimed to distinguish RA subtypes based on peripheral blood (PB) gene expression profiles in comparison with a pathogen-response transcriptional program. PB was obtained from 35 RA patients and 15 healthy individuals. For expression profiling we used DNA microarrays. A combined cluster analysis of RA and control samples together with samples from a viral infection model revealed that the gene expression profile of a subgroup of RA patients (RA(A)) was reminiscent to that of poxvirus-infected macaques. Statistical analysis, followed by Gene Ontology analysis of the RA(A) patients confirmed that these patients form a distinct group, with activation of several host defense mechanisms that resemble a common host-pathogen response. Analysis of the promoter region of genes that were overexpressed in the RA(A) patients, revealed an enrichment of transcription factor binding sites for NF kappaB and interferon-activated transcription factors. Moreover, this subgroup of RA patients expressed significantly increased titers of anti-cyclic citrullinated peptide antibodies. We conclude that activation of a host-pathogen response defines a subgroup of RA patients characterized by increased autoreactivity against citrullinated proteins.
Sujet(s)
Polyarthrite rhumatoïde/classification , Polyarthrite rhumatoïde/génétique , Analyse de profil d'expression de gènes , Agranulocytes/métabolisme , Facteurs de transcription/métabolisme , Animaux , Polyarthrite rhumatoïde/sang , Études cas-témoins , Analyse de regroupements , Femelle , Régulation de l'expression des gènes , Gènes viraux , Interactions hôte-parasite , Humains , Agranulocytes/cytologie , Macaca/virologie , Mâle , Adulte d'âge moyen , Séquençage par oligonucléotides en batterie , Régions promotrices (génétique) , Variole , Facteurs de transcription/génétiqueRÉSUMÉ
OBJECTIVE: The response of rheumatoid arthritis (RA) patients to treatment with neutralising antibodies to tumour necrosis factor alpha (TNFalpha) is highly variable. The underlying mechanism for therapy responsiveness is currently unknown. We therefore evaluated the relationship between baseline molecular profiles of synovial tissues from RA patients and the clinical response to treatment with infliximab. METHODS: Synovial biopsies were obtained by arthroscopy from 18 RA patients with active disease (28 joint count Disease Activity Score (DAS28) > or = 3.2) before initiation of treatment with infliximab. All patients were on stable methotrexate treatment. Clinical response at 16 weeks was defined as a reduction in DAS28 of > or = 1.2, non-response as reduction in DAS28 < 1.2. Large-scale gene expression profiling using microarrays was performed on synovial tissue samples. To identify biological processes in synovial biopsies that could discriminate between responders and non-responders, we performed pathway analysis on the expression profiles. RESULTS: A total of 12 patients responded to therapy, while 6 patients failed to fulfil the response criteria. We identified several biological processes, related to inflammation, which were up-regulated in patients who responded to therapy, compared to those who did not show clinical improvement. CONCLUSION: These results indicate that patients with a high level of tissue inflammation are more likely to benefit from anti-TNFalpha treatment.
Sujet(s)
Anticorps monoclonaux/usage thérapeutique , Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Synovite/traitement médicamenteux , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Polyarthrite rhumatoïde/génétique , Polyarthrite rhumatoïde/anatomopathologie , Sites de fixation , Biopsie , Association de médicaments , Femelle , Études de suivi , Analyse de profil d'expression de gènes/méthodes , Humains , Infliximab , Mâle , Méthotrexate/usage thérapeutique , Adulte d'âge moyen , Pronostic , Indice de gravité de la maladie , Membrane synoviale/métabolisme , Membrane synoviale/anatomopathologie , Synovite/génétique , Synovite/anatomopathologie , Facteurs de transcription/métabolisme , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Rheumatoid arthritis (RA) is a heterogeneous disease with unknown cause. AIM: To identify peripheral blood (PB) gene expression profiles that may distinguish RA subtypes. METHODS: Large-scale expression profiling by cDNA microarrays was performed on PB from 35 patients and 15 healthy individuals. Differential gene expression was analysed by significance analysis of microarrays (SAM), followed by gene ontology analysis of the significant genes. Gene set enrichment analysis was applied to identify pathways relevant to disease. RESULTS: A substantially raised expression of a spectrum of genes involved in immune defence was found in the PB of patients with RA compared with healthy individuals. SAM analysis revealed a highly significant elevated expression of interferon (IFN) type I regulated genes in patients with RA compared with healthy individuals, which was confirmed by gene ontology and pathway analysis, suggesting that this pathway was activated systemically in RA. A quantitative analysis revealed that increased expression of IFN-response genes was characteristic of approximately half of the patients (IFN(high) patients). Application of pathway analysis revealed that the IFN(high) group was largely different from the controls, with evidence for upregulated pathways involved in coagulation and complement cascades, and fatty acid metabolism, while the IFN(low) group was similar to the controls. CONCLUSION: The IFN type I signature defines a subgroup of patients with RA, with a distinct biomolecular phenotype, characterised by increased activity of the innate defence system, coagulation and complement cascades, and fatty acid metabolism.
Sujet(s)
Polyarthrite rhumatoïde/génétique , Analyse de profil d'expression de gènes , Interféron de type I/génétique , Séquençage par oligonucléotides en batterie , Régulation positive , Adulte , Polyarthrite rhumatoïde/immunologie , Coagulation sanguine/génétique , Activation du complément/génétique , Femelle , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
Given the heterogeneous nature of multiple sclerosis (MS), we applied DNA microarray technology to determine whether variability is reflected in peripheral blood (PB) cells. In this study, we studied whole-blood gene expression profiles of 29 patients with relapsing-remitting MS (RRMS) and 25 age- and sex-matched healthy controls. We used microarrays with a complexity of 43K cDNAs. The data were analyzed using sophisticated pathway-level analysis in order to provide insight into the deregulated peripheral immune response programs in MS. We found a remarkable elevated expression of a spectrum of genes known to be involved in immune defense in the PB of MS patients compared to healthy individuals. Cluster analysis revealed that the increased expression of these genes was characteristic for approximately half of the patients. In addition, the gene signature in this group of patients was comparable with a virus response program. We conclude that the transcriptional signature of the PB cells reflects the heterogeneity of MS and defines a sub-population of RRMS patients, who exhibit an activated immune defense program that resembles a virus response program, which is supportive for a link between viruses and MS.